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Abstract
Mathematical models are increasingly being used to simulate events in the exposure-response continuum, and to support quan-
titative predictions of risks to human health. Physiologically based pharmacokinetic (PBPK) models address that portion of the
continuum from an external chemical exposure to an internal dose at a target site. Essential data needed to develop a PBPK model
include values of key physiological parameters (e.g., tissue volumes, blood flow rates) and chemical specific parameters (rate of
chemical absorption, distribution, metabolism, and elimination) for the species of interest. PBPK models are commonly used to: (1)
predict concentrations of an internal dose over time at a target site following external exposure via different routes and/or durations;
(2) predict human internal concentration at a target site based on animal data by accounting for toxicokinetic and physiological
differences; and (3) estimate variability in the internal dose within a human population resulting from differences in individual
pharmacokinetics. Himmelstein et al. [M.W. Himmelstein, S.C. Carpenter, P.M. Hinderliter, Kinetic modeling of beta-chloroprene
metabolism. I. In vitro rates in liver and lung tissue fractions from mice, rats, hamsters, and humans, Toxicol. Sci. 79 (1) (2004)
18–27; M.W. Himmelstein, S.C. Carpenter, M.V. Evans, P.M. Hinderliter, E.M. Kenyon, Kinetic modeling of beta-chloroprene
metabolism. II. The application of physiologically based modeling for cancer dose response analysis, Toxicol. Sci. 79 (1) (2004)
28–37] developed a PBPK model for chloroprene (2-chloro-1,3-butadiene; CD) that simulates chloroprene disposition in rats, mice,
hamsters, or humans following an inhalation exposure. Values for the CD-PBPK model metabolic parameters were obtained from in
vitro studies, and model simulations compared to data from in vivo gas uptake studies in rats, hamsters, and mice. The model estimate
for total amount of metabolite in lung correlated better with rodent tumor incidence than did the external dose. Based on this PBPK
model analytical approach, Himmelstein et al. [M.W. Himmelstein, S.C. Carpenter, M.V. Evans, P.M. Hinderliter, E.M. Kenyon,
Kinetic modeling of beta-chloroprene metabolism. II. The application of physiologically based modeling for cancer dose response
analysis, Toxicol. Sci. 79 (1) (2004) 28–37; M.W. Himmelstein, R. Leonard, R. Valentine, Kinetic modeling of -chloroprene
metabolism: default and physiologically-based modeling approaches for cancer dose response, in: IISRP Symposium on Evaluation
of Butadiene & Chloroprene Health Effects, September 21, 2005, TBD—reference in this proceedings issue of Chemical–Biological
Interactions] propose that observed species differences in the lung tumor dose–response result from differences in CD metabolic
rates. The CD-PBPK model has not yet been submitted to EPA for use in developing the IRIS assessment for chloroprene, but
is sufficiently developed to be considered. The process that EPA uses to evaluate PBPK models is discussed, as well as potential
applications for the CD-PBPK model in an IRIS assessment.
Published by Elsevier Ireland Ltd.
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1. Introduction
The mission of the EPA to protect human health
and the environment depends on the availability of
quality data for quantitative characterization of the
dose–response relationship. Biologically based mathe-
0009-2797/$ – see front matter. Published by Elsevier Ireland Ltd.
doi:10.1016/j.cbi.2007.01.016
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Fig. 1. The role of quantitative modeling and simulation in research is illustrated in this schematic of the relationship between a real system, a
conceptualization of the system (the theoretical model), and the data. A BBDR model evolves from a qualitative (conceptual) model to a quantitative
(mathematical) model of the mode of action, and therefore serves the role of both of these compartments in the figure. [Reprinted with permission
from John Wiley & Sons, Inc. from the book [1], Copyright© 1992 Wiley-Liss, Inc.].
matical models are increasingly being used to maximize
the utility of the available data for this characterization,
and to identify data gaps. This presentation provides a
brief overview of the development, use, and evaluation
of physiologically based pharmacokinetic (PBPK1)
models in risk assessment, and potential applications of
a PBPK model for chloroprene.
2. Development and use of PBPK models in risk
assessment
Computer models of biological systems begin with
a conceptual (i.e., qualitative) representation of the
components and behaviors of a real system. In an itera-
tive process, this qualitative conception is progressively
replaced with mathematical representations (i.e., the
quantitative model) that simulate system behavior for
comparison with experimental observations. Keen and
1 Some people prefer the acronyms PBTK and PBTD, replacing
“pharmacokinetic” and “pharmacodynamic” terms with “toxicoki-
netic” and “toxicodynamic” to distinguish models for toxic substances
from those for pharmaceuticals. The Greek root “pharmakon”, how-
ever, means either poison or drug, and although contemporary use
associates the prefix “pharmaco-” most commonly with a medicine,
both PBPK and PBTK monikers are correct, and the choice of which
to use is a matter of personal preference.
Spain [1] illustrate this iterative process in model devel-
opment in Fig. 1.
In risk assessment, the “system” behaviors to be sim-
ulated are the spatial and temporal sequence of events
from the release of a chemical in the environment to
an adverse effect in humans. For practical reasons, this
continuous sequence is somewhat arbitrarily divided into
discrete stages, each represented by a different subset of
computer models, as illustrated in Fig. 2. The dosimetry
models in Fig. 2 of interest here are called physio-
logically based pharmacokinetic (PBPK, see footnote
Fig. 2. Computer models for various subgroupings of the risk assess-
ment events from release of a toxin to the environment to an adverse
effect in humans.
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1) models and the dynamic models, biologically based
dose–response (BBDR) models (also known as physio-
logically based pharmacodynamic (PBPD, see footnote
1) models) [2]. PBPK models simulate events beginning
with the absorption of the external dose and ending with
an internal level of a chemical at a tissue or target site (the
internal dose). The “PB” in PBPK means that the model
attempts to represent real physiological processes and
biological tissues. The “PK” refers to the pharmacoki-
netic processes by which the body affects a chemical’s
internal disposition. BBDR models simulate the down-
stream events from the internal dose at a target site to the
chemical’s adverse effect(s) on the body, i.e., how the
chemical affects the body. Both PBPK and BBDR mod-
els provide useful conceptual frameworks to organize the
extant kinetic and toxicity data, and to facilitate identi-
fication of the “mode of action” (MOA) [3]. The MOA
is a description of the key events (as in critical path) at
the relevant level of biological organization (generally
at the cell or molecular level) that leads to the adverse
effects. The MOA is a subset of the complete network
of all associated physiological and biochemical events.
Generally, a PBPK model can estimate many dif-
ferent measures of the internal dose or “dose metric”
(e.g., average blood concentration, peak tissue concen-
tration, total amount metabolized). The choice of which
dose metric to use in a risk assessment is determined by
the proposed MOA. Conversely, insights into the MOA
are often obtained by comparing how closely differ-
ent PBPK model dose metrics correlate to the adverse
response(s).
Common applications of PBPK models in risk assess-
ment are illustrated in Fig. 3, and include: (1) predicting
the internal tissue level that would result from an external
exposure in a test animal; (2) predicting a human equiva-
lent internal tissue level by extrapolating from the animal
kinetic data for external versus internal dose relationship;
(3) predicting an animal or human internal dose level
for one route of exposure (e.g., inhalation) based upon
kinetic data from a different route of exposure (e.g., oral
exposure); and (4) predicting variability in the human
internal dose within a population due to individual differ-
ences in key physiological processes to identify sensitive
sub-populations.
PBPK models require certain basic physiological data
and chemical specific kinetic data for their development.
The studies needed to develop a PBPK model, however,
may be more cost effective and less time consuming
than multiple animal bioassays (especially for assessing
potential effects from inhalation exposures), and provide
an ethical alternative to human dose–response studies.
For a detailed discussion and examples of PBPK
model development and use in risk assessment, the
reader is referred to a recent EPA report titled
Fig. 3. Sample PBPK model applications in risk assessment.
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Fig. 4. Model evaluation—highlights of a six step process (with sample subheadings) for evaluating PBPK models. Adapted from [6].
“Approaches for the Application of Physiologically
Based Pharmacokinetic (PBPK) Models and Supporting
Data in Risk Assessment” [4].
3. Evaluation of PBPK models used in IRIS
assessments
Quality criteria for the evaluation of PBPK models for
use in risk assessment have been proposed by Clark et al.
[5], and are summarized in Fig. 4. These include model
purpose, biological characterization and model structure,
mathematical description, computer implementation,
model fit to available data, and specialized analyses (e.g.,
uncertainty and variability analysis, sensitivity analysis).
EPA emphasizes the importance of model transparency
and the availability of model code, command files (i.e.,
run conditions), and software. This information is needed
to assure quality control for coding errors or structural
flaws (such as lack of mass balance), and for peer review
(external confirmation of model behavior and results).
Parameter values must also be fully referenced and dis-
cussed with respect to the intended use of the model,
the choices made, and alternative values. In all cases,
the quality of a model depends upon the quality of the
data used to calibrate and test the model for predictive
capability. This is a major focus in a model evaluation.
Sensitivity analysis is used in a model evaluation to
identify the parameters that have the greatest impact on
a specified model output (i.e., a particular dose metric).
These results guide and support decisions on the con-
fidence in the model predictions relative to how well
supported are critical parameters with data, and which
parameter estimates warrant the costs to acquire more
supporting data. EPA is increasingly conducting an ini-
tial “scoping” of available PBPK models and potential
uses early on in the development of a risk assessment,
in large part because resource (both time and money)
must be carefully planned if further model development
or data are needed for a specific application. An illus-
tration of EPA’s process for model evaluation during the
development of an IRIS (Integrated Risk Information
System) assessment is presented in Fig. 5. IRIS is an elec-
tronic database containing information on human health
effects that may result from exposure to various chem-
icals in the environment. EPA’s process for developing
IRIS assessments is available on-line [6].
Each IRIS assessment is assigned a Chemical
Manager (CM) who develops the assessment and
shepherds it though the multiple layers of review. EPA’s
National Center for Environmental Assessment (NCEA)
formed a Pharmacokinetic Working Group (PKWG)
to assist the CM in their evaluation of PBPK models.
Fig. 5 illustrates the initial step in this evaluation (the
scoping meeting) where the CM and the PKWG review
the available kinetic data, proposed MOA, available
models, and proposed model applications. If the model
is acceptable “as is” or if resources are available to
further develop the model and/or obtain needed data
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Fig. 5. PBPK model evaluation and the IRIS assessment development process—the initial scoping meeting.
for a particular application, then the model progresses
through a planning, implementation, and review of its
use in deriving IRIS reference values.
There are currently no general criteria to determine
when a model is “good enough” for use in a risk assess-
ment. These determinations require scientific judgment
and expertise, and are made on a case-by-case basis
within the context of the proposed application and the
alternatives. Work continues, however, to develop crite-
ria and guidance for model evaluation especially in key
areas of model specification, calibration, and analysis as
evidenced by a recent international workshop on uncer-
tainty and variability analysis in PBPK models [7]. EPA’s
PKWG has also compiled an historical accounting of
PBPK and classical PK models used in IRIS assessments
to-date, and the impact on reference values compared
with use of the default uncertainty factors [8].
4. Chloroprene and the chloroprene PBPK
model
Chloroprene (CD), a 2-chloro analog of 1,3-
butadiene, is used exclusively in the production of
neoprene elastomers, which are polymerized forms of
polychloroprene. Polychloroprene is a synthetic rubber
used in coverings or in formulations where chemical,
oil, or weather resistance is needed (e.g., wire and cable
covers, gaskets, adhesives, caulks, flame-resistant cush-
ioning) [9,10]. CD is absorbed via inhalation, oral, and
dermal routes. Parent CD is metabolized by mixed func-
tion oxidases to (1-chloroethenyl)-oxirane (1-CEO), a
potentially genotoxic epoxide [11], and another metabo-
lite, 2-chloro-2-ethenyloxirane (2-CEO). 1-CEO and
2-CEO are hydrolyzed by epoxide hydrolase, and 2-CEO
is further conjugated with glutathione.
The hazardous effects from exposure to CD have been
studied in occupational cohorts and animal bioassays
[12; see I. Pagan in this issue for a discussion of CD
toxicity]. Human data are limited. Animal studies report
dose–response non-cancer adverse effects from inhala-
tion exposures to CD consisting of lesions or functional
damage to the lung, kidney, and nasal tissues. Signifi-
cantly increased tumor incidence has also been observed
in these and other tissues in B6C3F1 mice and F344 rats,
but not in Syrian hamsters or Wistar rats.
To address the divergent responses and support
extrapolation of the animal dose–response to predict
the human dose–response, a PBPK model for chloro-
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prene (CD-PBPK) was developed by Himmelstein et al.
[13,14]. The CD-PBPK model simulates disposition of
chloroprene in rats, mice, hamsters, and humans follow-
ing an inhalation exposure. This model has not yet been
formally submitted to EPA for evaluation, so the dis-
cussion here is limited to some initial comments on the
published model and its potential use in the chloroprene
IRIS assessment.
The CD-PBPK model is a standard, perfusion lim-
ited model of the Ramsey and Andersen genre [15] with
five compartments—liver, lung, fat, slowly and rapidly
perfused tissues. CD metabolism is represented with
Michaelis–Menten equations for saturable kinetics and
as occurring only in the lung and liver compartments.
The model estimates CD concentrations in each tissue
compartment and blood, and is coded in the Advanced
Continuous Simulation Language (ACSL2).
Model parameters were developed as follows [13,14]:
(1) tissue-to-blood partition coefficients were calcu-
lated from experimentally derived tissue-to-air data;
(2) metabolic parameters were obtained from in vitro
metabolism data for rats, mice, and humans; in vivo
parameter values were scaled from in vitro data based
upon the microsomal protein content in vivo; (3) liver
microsomal protein content values for each species were
obtained from the literature (microsomal protein content
for rats was used for the hamster); (4) all species were
assigned the same value for lung microsomal protein/g
tissue; and (5) standard physiologic values were used to
parameterize the model. In vivo gas uptake data in rats
and mice were used to calibrate the model. To fit the
experimental gas uptake data, only the rates of alveo-
lar ventilation and cardiac output needed to be further
adjusted. No further adjustment was needed to the other
physiological and metabolic parameters obtained from
in vitro experimentation.
5. Potential applications of the CD-PBPK models
in the IRIS assessment for chloroprene
The CD-PBPK model estimates dose metrics for par-
ent compound in blood and tissue compartments, and
total amount metabolized in either the lung or liver.
Based on these dose metrics, the following potential
applications of the CD-PBPK model could be considered
in developing the IRIS assessment for chloroprene:
1. Evaluate the mode of action by correlating parent or
total amount metabolized with cancer and non-cancer
endpoints.
2 ACSL version 11.8.4, AEgis Technologies Group, Huntsville, AL.
2. Elucidate observed species differences in the external
dose–response relationship.
3. Extrapolate the animal dose–response relationship to
estimate the human dose–response based on the most
relevant internal dose metric for the proposed MOA,
the human equivalent concentration associated with
a NOAEL or benchmark response level (as a point of
departure), and application of any additional uncer-
tainty factors to derive an estimate of an external
exposure for a given duration to the human popu-
lation (including susceptible subgroups) that is likely
to be without an appreciable risk of adverse health
effects over a lifetime.
4. Estimate human variability in chemical disposition
within a population by using PBPK model parameter
distributions (instead of point estimates) to repre-
sent variability in intra-population rates of chemical
absorption, distribution, metabolism and/or elimina-
tion.
Route-to-route extrapolation of the dose–response
relationship (i.e., from an inhalation route to an oral
route) is not critical for chloroprene since chloroprene
is highly unstable in water, and exposure and uptake by
the oral route is considered unlikely.
Himmelstein et al. [16] demonstrated a greater corre-
lation between the amount of CD metabolized in lung
(mg CD metabolized/g lung/day) for each species and
the tumor incidence than between external dose and
tumor incidence. These results support the hypothesis
(and the proposed MOA) that the observed differ-
ence between rat, mice, and hamster lung tumor
dose–response are due to different rates and compo-
sition of CD metabolizing enzymes. Mice metabolize
more parent CD than rats or hamsters, and in accordance
with an MOA that proposes a metabolite as the puta-
tive toxicant, have a markedly greater incidence of lung
tumors. The CD-PBPK model was then exercised with
parameters set to human values (some of which were
scaled from or the same as the rodent values) to predict
the internal dose in humans that would yield a speci-
fied response (e.g., benchmark response level of 10%)
using the dose metric of total amount of metabolite pro-
duced in the lung, and then the external dose that would
result in that level of internal dose. Himmelstein et al.
[16, in this proceedings] did this work, and compared
total amount metabolized in rodent and human lung and
liver to the available response data from animal bioas-
says (tumor incidence) or human epidemiology studies
(mortality rates from respiratory cancer).
Strengths in the Himmelstein et al [13,14,16] CD-
PBPK model include: (1) the fits to the rodent in vivo gas
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uptake data using parameter estimates that were derived
from in vitro studies with little need for further adjust-
ment to parameter values; (2) the insights gained that an
active metabolite is the likely toxicant as evidenced by
the higher correlation between total amount metabolized
in lung and lung tumor incidence compared to external
dose and lung tumor incidence; and (3) support for the
apparent species differences being due to differences in
tissue metabolic rates.
In the full evaluation of a CD-PBPK model submit-
ted to EPA for use in an IRIS assessment, the model
assumptions and results would be reviewed in detail for
scientific support of the assumptions about the metabolic
pathways, the parameter values for tissue microsomal
protein content in each species, and the need to reduce
alveolar ventilation rate to fit the gas uptake data. The
assumptions underlying the correlation of internal dose
to the human lung cancer mortality data analysis will also
be reviewed, but even if some of these assumptions are
tenuous and the results not currently acceptable for use
in an EPA assessment, these kinds of analyses expand the
utility of PBPK models, and are encouraged and neces-
sary to advance the discipline and to identify future data
and research needs.
Areas of additional research (or application of the
model) could include modeling the 1-CEO metabolism
as a potential determinant of species differences, and
addition of the kidney compartment. Data on parent or
metabolite levels in vivo would obviously advance the
model development and the confidence in the accuracy
of the predictions, however, it is recognized that the
reactivity of the parent compound and the spontaneous
aqueous hydrolysis of 2-CEO [17,18] confound in vivo
measurement.
In conclusion, PBPK models are increasingly being
used to develop quantitative dose–response relation-
ships and reference values to protect human health.
The EPA encourages the development of PBPK mod-
els for use in risk assessment, and is actively improving
model evaluation and analytical tools and expertise. In
its current state of development, the CD-PBPK model
developed by Himmelstein et al. [13,14,16] has poten-
tial for use in the development of the IRIS assessment
for chloroprene based on the hypothesis that differ-
ences in metabolic rates are determinants of the observed
species differences in dose–response. This hypothe-
sis has been demonstrated for other chemicals (e.g.,
vinyl chloride), and PBPK models that account for
the different metabolic rates have been successfully
used to derive IRIS reference values [19]. Further
research and development of the CD-PBPK model
is encouraged to advance the understanding of the
chloroprene MOA and the models use in risk assess-
ment.
References
[1] R.E. Keen, J.D. Spain, Computer Simulation in Biology, Wiley-
Liss, Inc., New York, USA, 1992, p. 7.
[2] US EPA, Glossary of Integrated Risk Information System (IRIS)
Terms, Available at: http://www.epa.gov/iris/gloss8.htm#b.
[3] R.S. DeWoskin, S. Barone Jr., H.J. Clewell, R.W. Setzer, Improv-
ing the development and use of biologically based dose response
models (BBDR) in risk assessment, Hum. Ecol. Risk Assess. 7
(5) (2001) 1091–1120.
[4] U.S. Environmental Protection Agency, Approaches for the
Application of Physiologically Based Pharmacokinetic (PBPK)
Models and Supporting Data in Risk Assessment, EPA/600/R-
05/043F, U.S. Environmental Protection Agency, Washing-
ton, DC, 2006, Available at: http://cfpub.epa.gov/ncea/cfm/
recordisplay.cfm?deid=135427.
[5] L.H. Clark, R.W. Setzer, H.A. Barton, Framework for evalua-
tion of physiologically-based pharmacokinetic models for use in
safety or risk assessment, Risk Anal. 24 (6) (2004) 1697–1717.
[6] US EPA, Integrated Risk Information System (IRIS) Home Page,
Available at: http://www.epa.gov/iris/index.html.
[7] US EPA, International Workshop on Uncertainty and Variabil-
ity in Physiologically Based Pharmacokinetic (PBPK) Models,
Research Triangle Park, NC, USA, October 31–November 2,
2006, Proceedings and white papers available at: http://www.epa.
gov/comptox/uvpkm/.
[8] R.S. DeWoskin, J.C. Lipscomb, C. Thompson, W. Chiu,
P. Schlosser, C. Smallwood, J. Swartout, L. Teuschler, A.
Marcus, in: J.C. Lipscomb, E.V. Ohanian (Eds.), Pharma-
cokinetic/Physiologically Based Pharmacokinetic Models in
Integrated Risk Information System Assessments, Chapter 15
in Toxicokinetics and Risk Assessment, CRC Press, ISBN:
0849337224, 2006.
[9] US Environmental Protection Agency, Health and Environmental
Effects Profile for 2-Chloro-1,3-Butadiene, EPA/600/x-84/112,
Environmental Criteria and Assessment Office, Office of Health
and Environmental Assessment, Office of Research and Devel-
opment, Cincinnati, OH, 1984.
[10] US Environmental Protection Agency, Health and Environmen-
tal Effects Document for 2-Chloro-1,3-Butadiene (Chloroprene),
ECAO-CIN-G037, Environmental Criteria and Assessment
Office, Office of Health and Environmental Assessment, Office
of Research and Development, Cincinnati, OH, 1989.
[11] M.W. Himmelstein, N.L. Gladnick, E.M. Donner, R.D.
Snyder, R. Valentine, In vitro genotoxicity testing of (1-
chloroethenyl)oxirane, a metabolite of beta-chloroprene, Chem.
Biol. Interact. 135/136 (2001) 703–713.
[12] I. Pagan, Chloroprene: overview of studies under consideration
for the development of an IRIS Assessment, in: IISRP Sympo-
sium on Evaluation of Butadiene & Chloroprene Health Effects,
September 21, 2005, TBD—reference in this proceedings issue
of Chemical–Biological Interactions.
[13] M.W. Himmelstein, S.C. Carpenter, P.M. Hinderliter, Kinetic
modeling of beta-chloroprene metabolism. I. In vitro rates in liver
and lung tissue fractions from mice, rats, hamsters, and humans,
Toxicol. Sci. 79 (1) (2004) 18–27.
[14] M.W. Himmelstein, S.C. Carpenter, M.V. Evans, P.M. Hinderliter,
E.M. Kenyon, Kinetic modeling of beta-chloroprene metabolism.
R.S. DeWoskin / Chemico-Biological Interactions 166 (2007) 352–359 359
II. The application of physiologically based modeling for cancer
dose response analysis, Toxicol. Sci. 79 (1) (2004) 28–37.
[15] J.C. Ramsey, M.E. Andersen, A physiologically based description
of the inhalation pharmacokinetics of styrene in rats and humans,
Toxicol. Appl. Pharmacol. 73 (1984) 159–175.
[16] M.W. Himmelstein, R. Leonard, R. Valentine, Kinetic modeling
of -chloroprene metabolism: default and physiologically-based
modeling approaches for cancer dose response, in: IISRP Sympo-
sium on Evaluation of Butadiene & Chloroprene Health Effects,
September 21, 2005, TBD—reference in this proceedings issue
of Chemical–Biological Interactions.
[17] L. Cottrell, B.T. Golding, T. Munter, W.P. Watson, In vitro
metabolism of chloroprene: species differences, epoxide stere-
ochemistry and a de-chlorination pathway, Chem. Res. Toxicol.
14 (11) (2001) 1552–1562.
[18] T. Munter, L. Cottrell, R. Ghai, B.T. Golding, W.P. Watson,
The metabolism and molecular toxicology of chloroprene, Chem.
Biol. Interact. (2006) (Epub ahead of print).
[19] U.S. Environmental Protection Agency, Toxicological Review
of Vinyl Chloride, EPA 635/R-00/004, U.S. Environmental Pro-
tection Agency, Washington, DC, 2000, Available online at:
http://www.epa.gov/iris/toxreviews/1001-tr.pdf.
